New combo aims to outsmart hard-to-treat breast cancer
NCT ID NCT04265872
First seen Feb 16, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This early-phase trial tests whether the drug bortezomib can make metastatic triple-negative breast cancer more sensitive to the immunotherapy pembrolizumab and chemotherapy cisplatin. About 20 women with advanced disease who have already received standard chemotherapy will receive bortezomib first, then the combination when their cancer progresses. The goal is to see if this approach can shrink tumors and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact
Conditions
Explore the condition pages connected to this study.